Enliven Therapeutics
Enliven Therapeutics is a biotech company focused on developing small molecule kinase inhibitors for cancer treatment, with ongoing clinical trials for its leading compounds, ELVN-001 and ELVN-002.
Services
Enliven Therapeutics specializes in the discovery and development of small molecule kinase inhibitors for cancer treatment. The company focuses on precision oncology to address unmet needs in cancer therapy. It is dedicated to developing therapies that improve the survival and overall well-being of cancer patients. Enliven Therapeutics is currently engaged in early-stage clinical trials as part of its development process.
Sector
The company operates within the biotechnology and pharmaceutical sectors, specifically targeting oncology. By concentrating on developing targeted therapies for cancer treatment via precision oncology, Enliven Therapeutics aims to provide innovative solutions to patients with chronic myeloid leukemia and other solid tumors.
Pipeline Programs
Enliven Therapeutics' pipeline includes two primary programs: the BCR-ABL program and the HER2 program. The BCR-ABL program features ELVN-001, a highly selective kinase inhibitor designed to treat chronic myeloid leukemia. The HER2 program includes ELVN-002, a CNS-penetrant and irreversible inhibitor targeting HER2 mutations in solid cancers. Both ELVN-001 and ELVN-002 are currently in Phase 1 clinical trials, demonstrating the company's commitment to advancing innovative cancer therapies.
Clinical Trials
Enliven Therapeutics is actively engaged in Phase 1 clinical trials for its two leading candidates, ELVN-001 and ELVN-002. These early-stage trials are crucial for testing the safety and efficacy of these small molecule kinase inhibitors in human subjects. The trials are an important step in the development process, aimed at bringing new treatments to the market for chronic myeloid leukemia and HER2-positive solid tumors.
Headquarters
Enliven Therapeutics is headquartered in Boulder, Colorado. This location serves as the base for its research, development, and administrative operations. The company benefits from Boulder’s vibrant biotech community and advanced scientific infrastructure.